Oragenics Financial Statements From 2010 to 2026

OGEN Stock  USD 0.78  0.03  4.00%   
Oragenics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Oragenics' valuation are provided below:
Gross Profit
-3.4 M
Market Capitalization
3.1 M
Enterprise Value Revenue
105.8267
Earnings Share
48.21
Quarterly Revenue Growth
(0.91)
We have found one hundred twenty available trending fundamental ratios for Oragenics, which can be analyzed and compared to other ratios and to its competitors. Self-guided Investors are advised to check out Oragenics' recent fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 1st of January 2026, Market Cap is likely to drop to about 680.4 M. In addition to that, Enterprise Value is likely to drop to about 668.3 M

Oragenics Total Revenue

37,653

Check Oragenics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oragenics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 37 K, Interest Expense of 56.5 K or Selling General Administrative of 4.3 M, as well as many indicators such as Price To Sales Ratio of 9.5 K, Dividend Yield of 5.0E-4 or Days Sales Outstanding of 42.17. Oragenics financial statements analysis is a perfect complement when working with Oragenics Valuation or Volatility modules.
  
Build AI portfolio with Oragenics Stock
Check out the analysis of Oragenics Correlation against competitors.
To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.

Oragenics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.4 M1.5 M10.7 M
Pretty Stable
Other Current Liabilities414.5 K211.2 K466.9 K
Slightly volatile
Total Current Liabilities1.6 M1.7 M1.8 M
Pretty Stable
Accounts Payable603 K1.1 M610.3 K
Slightly volatile
Cash821.6 K864.8 K9.7 M
Very volatile
Cash And Short Term Investments821.6 K864.8 K9.7 M
Very volatile
Common Stock Total Equity110.8 K105.5 K54.5 K
Slightly volatile
Common Stock Shares OutstandingM6.6 M1.4 M
Slightly volatile
Liabilities And Stockholders Equity1.4 M1.5 M10.7 M
Pretty Stable
Other Current Assets810 K607.7 K835.3 K
Slightly volatile
Other Stockholder Equity227.4 M216.6 M127.4 M
Slightly volatile
Total Liabilities1.8 M1.7 M1.9 M
Pretty Stable
Total Current Assets1.4 M1.5 M10.5 M
Very volatile
Common Stock11.9 K12.6 K32.9 K
Very volatile
Property Plant Equipment228.1 K421.7 K188.9 K
Slightly volatile
Short and Long Term Debt Total573 K328.5 K788.5 K
Pretty Stable
Net ReceivablesK6.3 K21.1 K
Slightly volatile
Short Term Debt497 K328.5 K682.7 K
Slightly volatile
Current Deferred Revenue12.2 K12.8 K31.1 K
Slightly volatile
Capital Surpluse110.2 M188.6 M113.2 M
Slightly volatile
Short and Long Term Debt198.4 K328.5 K152.6 K
Slightly volatile
Net Invested Capital110.8 K116.6 K4.6 M
Slightly volatile
Capital Stock11.9 K12.6 K4.7 M
Slightly volatile
Non Current Liabilities Other465.8 K444.4 K599.5 K
Slightly volatile

Oragenics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization37 K38.9 K51.1 K
Slightly volatile
Interest Expense56.5 K29.8 K93.2 K
Slightly volatile
Selling General Administrative4.3 M6.4 M4.4 M
Slightly volatile
Other Operating Expenses11.3 M10.6 M12.6 M
Slightly volatile
Research Development6.7 M4.1 MM
Slightly volatile
Total Operating Expenses9.9 M10.6 M11 M
Slightly volatile
Cost Of RevenueM4.1 M3.2 M
Slightly volatile
Selling And Marketing Expenses66.7 K70.2 K111.9 K
Pretty Stable
Discontinued Operations25.9 K27.2 K66.7 K
Slightly volatile
Interest Income43.6 K45.9 K88.6 K
Slightly volatile
Extraordinary Items887 K1.7 M952.4 K
Slightly volatile
Preferred Stock And Other Adjustments1.1 M1.3 M1.4 M
Slightly volatile

Oragenics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.3 M3.5 M9.6 M
Slightly volatile
End Period Cash Flow821.6 K864.8 K9.7 M
Very volatile
Stock Based Compensation490.2 K516 K1.1 M
Slightly volatile
Issuance Of Capital Stock8.2 M6.7 M11.9 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.5 K9.1 K9.4 K
Slightly volatile
Dividend Yield5.0E-47.0E-44.0E-4
Slightly volatile
Days Sales Outstanding42.1733.7224.8877
Slightly volatile
Average Payables1.3 M1.2 M669.7 K
Slightly volatile
Stock Based Compensation To Revenue25.5224.312.9049
Slightly volatile
Capex To Depreciation2.453.281.9713
Pretty Stable
EV To Sales9.5 KK9.2 K
Slightly volatile
Inventory Turnover2.781.721.8657
Pretty Stable
Days Of Inventory On Hand178219245
Pretty Stable
Payables Turnover3.773.59451.723
Slightly volatile
Sales General And Administrative To Revenue13713052.3102
Slightly volatile
Average Inventory201.9 K184.9 K176.2 K
Slightly volatile
Research And Ddevelopement To Revenue389370126
Slightly volatile
Capex To Revenue1.171.120.6884
Very volatile
Cash Per Share0.120.1306280
Slightly volatile
Days Payables Outstanding96.47102K
Pretty Stable
Income Quality0.860.81350.7473
Pretty Stable
Current Ratio0.830.87429.197
Pretty Stable
Receivables Turnover19.8111.220.8978
Slightly volatile
Capex Per Share0.06930.0733.2412
Slightly volatile
Average Receivables3.8 KK24.6 K
Slightly volatile
Revenue Per Share0.01830.019226.3343
Slightly volatile
Interest Debt Per Share0.05140.054154.7887
Slightly volatile
Debt To Assets0.430.22310.4327
Slightly volatile
Operating Cycle32.0333.72122
Slightly volatile
Days Of Payables Outstanding96.47102K
Pretty Stable
Ebt Per Ebit0.831.00091.0501
Pretty Stable
Long Term Debt To Capitalization15.8917.8819.4917
Slightly volatile
Quick Ratio0.830.87429.1159
Pretty Stable
Net Income Per E B T0.740.90.958
Pretty Stable
Cash Ratio0.490.51348.6544
Slightly volatile
Days Of Inventory Outstanding178219245
Pretty Stable
Days Of Sales Outstanding42.1733.7224.8877
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.161.0278
Slightly volatile
Fixed Asset Turnover5.753.455.9603
Slightly volatile
Debt Ratio0.430.22310.4327
Slightly volatile
Price Sales Ratio9.5 K9.1 K9.4 K
Slightly volatile
Asset Turnover0.00830.00870.107
Slightly volatile

Oragenics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap680.4 M1.4 B765.5 M
Slightly volatile
Enterprise Value668.3 M1.3 B752 M
Slightly volatile

Oragenics Fundamental Market Drivers

Oragenics Upcoming Events

17th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Oragenics Financial Statements

Oragenics investors utilize fundamental indicators, such as revenue or net income, to predict how Oragenics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue12.8 K12.2 K
Cost Of Revenue4.1 MM
Stock Based Compensation To Revenue 24.30  25.52 
Sales General And Administrative To Revenue 130.32  136.83 
Research And Ddevelopement To Revenue 370.27  388.79 
Capex To Revenue 1.12  1.17 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(325.85)(309.56)

Pair Trading with Oragenics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oragenics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oragenics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Oragenics Stock

  0.82RAC Race OncologyPairCorr
  0.72VALN Valneva SE ADRPairCorr

Moving against Oragenics Stock

  0.86DSGN Design TherapeuticsPairCorr
  0.8DNTH Dianthus TherapeuticsPairCorr
  0.79VCYT VeracytePairCorr
  0.760P6S Bayer AG NAPairCorr
  0.74VERA Vera TherapeuticsPairCorr
The ability to find closely correlated positions to Oragenics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oragenics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oragenics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oragenics to buy it.
The correlation of Oragenics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oragenics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oragenics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oragenics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Oragenics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oragenics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oragenics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oragenics Stock:
Check out the analysis of Oragenics Correlation against competitors.
To learn how to invest in Oragenics Stock, please use our How to Invest in Oragenics guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oragenics. If investors know Oragenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oragenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
48.21
Quarterly Revenue Growth
(0.91)
Return On Assets
(0.71)
Return On Equity
(1.69)
The market value of Oragenics is measured differently than its book value, which is the value of Oragenics that is recorded on the company's balance sheet. Investors also form their own opinion of Oragenics' value that differs from its market value or its book value, called intrinsic value, which is Oragenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oragenics' market value can be influenced by many factors that don't directly affect Oragenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oragenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Oragenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oragenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.